Neurocrine and Voyager Collaborate to Develop and Commercialize VY-AADC & VY-FXN01 for Parkinson's & Friedreich's Ataxia Disease
Shots:
- Voyager to receive $165M upfront including $115M in cash- $50M equity investment at $11.96/share and $1.7B milestones for its four gene therapy programs including VY-AADC & VY-FXN01. Additionally- Neurocrine to fund the two undisclosed gene therapy programs and Voyager to receive milestone and royalties on its WW sales
- Neurocrine to fund P-II/III & P-I for VY-AADC (RESTORE-1) study & VY-FXN01 respectively. Post P-II &P-I completion- Voyager has an option for co-commercialization with 50/50 & 60/40 cost-profit (Neurocrine/ Voyager) sharing in the US for VY-AADC & VY-FXN01 respectively. In case of non-exercising of an option- Vogayer will grant WW & US rights of VY-AADC & VY-FXN01 respectively to Neurocrine for milestone and royalties
- Voyager’s VY-AADC & VY-FXN01 are gene therapy products targeted for direct delivery of AADC gene in neurons & for controlling FXN protein levels respectively
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
